Rilapladib is a lipoprotein-associated phospholipase A2 inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. It is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. Reference standards of Rilapladib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Rilapladib - API Standards [catalogue_number] => PA 18 1280000 [category_ids] => ,75,76,78,70,82, [chemical_name] => [weight] => 735.81 [form] => C40H38F5N3O3S [cas] => 412950-08-4 [pslug] => 412950-08-4-rilapladib-api-pa181280000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 18 1280000
CAS :
Molecular Formula : C40H38F5N3O3S
Molecular Weight : 735.81
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
